WO2006122485A1 - Préparation pharmaceutique pour le traitement du diabète et procédé de mise en œuvre dudit traitement - Google Patents

Préparation pharmaceutique pour le traitement du diabète et procédé de mise en œuvre dudit traitement Download PDF

Info

Publication number
WO2006122485A1
WO2006122485A1 PCT/CN2006/000952 CN2006000952W WO2006122485A1 WO 2006122485 A1 WO2006122485 A1 WO 2006122485A1 CN 2006000952 W CN2006000952 W CN 2006000952W WO 2006122485 A1 WO2006122485 A1 WO 2006122485A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
parts
glibenclamide
pharmaceutical composition
added
Prior art date
Application number
PCT/CN2006/000952
Other languages
English (en)
Chinese (zh)
Inventor
Zhang Zou
Quyi Zhong
Hong Su
Guihua Chen
Yaoxin Zheng
Original Assignee
Guangzhou Zhongyi Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Zhongyi Pharmaceutical Company Limited filed Critical Guangzhou Zhongyi Pharmaceutical Company Limited
Publication of WO2006122485A1 publication Critical patent/WO2006122485A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a pharmaceutical composition, and more particularly to a Chinese and Western medicine combination composition for treating diabetes. It belongs to the technical field of medicines.
  • Diabetes which is called “diabetes disease” by Chinese medicine, is a common endocrine and metabolic disease characterized by high blood sugar, which is caused by absolute or relative deficiency of insulin.
  • the main clinical symptoms are: polyuria, polydipsia, polyphagia, weight loss.
  • the incidence of cardiovascular and cerebrovascular diseases, blindness and mortality in diabetic patients are 2 to 5 times higher, and the rate of lower extremity ulcers and amputation is 20 times higher.
  • diabetes has become the third largest non-communicable disease after relaying cardiovascular diseases and tumors in developed countries, and it is a worldwide public health problem that seriously threatens human health.
  • the global incidence of diabetes is about 120 million in 1994, about 135 million in 1997, about 175 million in 2000, and is expected to reach 239 million in 2010, and the number of cases will increase by 200% in developing countries, China, India, Some developing countries in Africa are the main affected areas. Both clinical and marketplaces urgently need an effective drug for the treatment of diabetes.
  • a thirst-quenching preparation is prepared, and the raw material composition thereof is pueraria 4000g, rehmannia 240g, astragalus 80g, trichosanthin 400g, corn whisker 400g, schisandra chinensis 80g, yam 40 g, glibenclamide 0.3 g composition.
  • the high dose of puerarin is used as a medicinal herb.
  • the single-flavored medicinal root is up to 4000 parts by weight, while the sum of the other medicinal herbs is only 1240 parts by weight.
  • the amount of pueraria root is much higher than that of Fangzhong.
  • the object of the present invention is achieved by the following technical solution - a pharmaceutical composition for treating diabetes, characterized in that the active ingredient of the pharmaceutical composition is as follows
  • the active ingredient of the preferred pharmaceutical composition of the present invention is prepared from the following ratios of the drug substance: - 600-900 parts by weight of Rehmannia glutinosa, 200-300 parts by weight of Astragalus, 100-150 parts by weight of Yam, 1000-1500 parts by weight of Radix Puerariae, 1000-1500 parts by weight of the smallpox, 1000-1500 parts by weight of the corn, 200-300 parts by weight of the Schisandra chinensis, and 0.2-1.0 parts by weight of glibenclamide.
  • the active ingredient of a further preferred pharmaceutical composition of the present invention is prepared from the following ratios of raw materials: 636 parts by weight of rehmannia, 212 parts by weight of astragalus, 106 parts by weight of yam, 1060 parts by weight of pueraria, 1060 parts by weight of geranium, 1060 parts by weight of corn, 1060 Parts by weight, 212 parts by weight of Schisandra chinensis, 1 part by weight of glibenclamide.
  • the pharmaceutical composition of the invention is based on the famous doctor Ye Tianshi of the Qing Dynasty, "Yuquan San” and “Xiaofang”, and functions to nourish the kidney and nourish the yin, and to replenish the vital energy.
  • Yam benefits lung spleen gas, lung and kidney yin, with the rehmannia glutinous spleen and Shengjin to tonify kidney water true yin;
  • Gegen Shengyang Shengjin help Huang Qi Sheng temper, scattered fine lungs, a total of medicine.
  • the schisandra chinensis is sour, the upper part can converge the lung yin, the lower can solidify the kidney and stimulate the body, the internal energy can stimulate the body and the nerves, the external energy can absorb the sweat, so that the water is not in a hurry, it is for the medicine; the whole party plays the kidney and nourish the yin and benefit The effect of Qishengjin.
  • this side can alleviate the symptoms of Chinese medicine for quenching thirst and achieve the purpose of lowering blood sugar.
  • the various flavors in the pharmaceutical composition of the present invention reasonably optimize the proportion and combination of the prescription, and the effect thereof is obviously superior to the "diabetes preparation" and glibenclamide, and provides for the treatment of diabetic patients.
  • a safe and effective formulation achieves the objectives of the present invention.
  • the pharmaceutical composition of the present invention can be formulated into a variety of clinically desirable dosage forms, including pills, pills, tablets, capsules, granules, soft capsules or powders, according to the technical requirements of the formulation.
  • Method 1 Take Radix Rehmanniae, Radix Puerariae, Trichosanthin, and Corn. Add boiling water for five hours, filter, and concentrate the filtrate to an appropriate amount. Astragalus, Schisandra, and Yam will be pulverized into a coarse powder. Mix well with the concentrate, dry, and pulverize into fine powder. Mix well. The water is pill, dried, added with glibenclamide, coated with black iron oxide, talc and an appropriate amount of binder, light-coated, and dried to form a pellet.
  • Method 2 Take Radix Rehmanniae, Radix Puerariae, Trichosanthin, and Corn. Add boiling water for five hours, filter, and concentrate the filtrate to the appropriate amount. Astragalus, Schisandra, Yam is pulverized into a coarse powder, mixed with the concentrate, dried, and pulverized into fine powder. Mix well. Pills were prepared by mechanical pelleting, dried, glibenclamide was added, black iron oxide, talc and appropriate amount of binder were applied, light-coated, and dried to prepare pellets.
  • Method 3 Take Radix Rehmanniae, Radix Puerariae, Trichosanthin, and Corn. Add boiling water for five hours, filter, and concentrate the filtrate to an appropriate amount. The scutellaria, schisandra, and yam are pulverized into coarse powder, mixed with the concentrate, dried, and pulverized into fine powder. Mix well. The granules were pelletized by a one-step granulator, and glibenclamide was added and compressed into pellets.
  • Method 4 Take Radix Rehmanniae, Radix Puerariae, Trichosanthin, and Corn. Add boiling water for five hours, filter, and concentrate the filtrate to an appropriate amount. Astragalus, Schisandra, Yam pulverized into fine powder, and concentrate into a granulator to make granules. Glyburide is added and compressed into pellets.
  • the "diabetes preparation” was prepared by the formulation of Example 4 of the publication CN1562188A.
  • the "preparation of the present invention” was prepared by the formulation of Example 1 of the present invention.
  • the "diabetes preparation” is a sample prepared according to the formulation of Example 4 of the publication CN1562188A; the “preparation of the present invention” is a powder prepared by the prescription of the embodiment 1 of the present invention. Dilute to the desired concentration with water before the experiment.
  • Glibenclamide Product of New Technology Development Company of Tianjin Pharmaceutical Research Institute; Streptozotcin (STZ) SIGMA Chemical Company, USA; Glucose Standard Solution: Shanghai Institute of Biological Products, Ministry of Health; Glucose Oxidase: From Guangdong Provincial Clinical Testing Center purchased; Cholesterol standard solution: produced by Beijing Chemical Plant; Enzymatic triglyceride determination kit (imported packaging): Shanghai Changzheng Medical Science Co., Ltd.; High fat emulsion composition: Cholesterol: 5g, Dutch import packaging Sodium deoxycholate: 0.3g, SERVA products, New York, USA; lard: 20g (commercially available), plus Tween 80 (Japanese product packaging) and 1, 2 propylene glycol (Shanghai Reagent First Factory) , formulated into 50ml emulsion, that is.
  • mice and SD rats were provided by the Medical Laboratory Animal Farm of the Guangdong Provincial Health Department.
  • mice Thirty healthy mice weighing 23 ⁇ 25g, male and female, were randomly divided into 4 groups: normal control group was intragastrically administrated with equal volume of normal saline, positive control glibenclamide 2mg/kg was administered, "thirst The preparation group is "administered by the stomach", and the dose is equivalent to 34.94g of crude drug/kg, containing 2mg of glibenclamide, and the "prescription of the present invention” group is administered with "the preparation powder of the present invention", and is administered. The dose is equivalent to 8.64g of crude drug per kg, containing 2mg of glibenclamide.
  • Healthy rats weighing 150-180 g were selected, male and female, and after 5 days of routine feeding, fasting for 12 hours.
  • streptozotocin 50 mg/5 ml/kg, prepared in pH 4.5 in citric acid buffer
  • was quickly injected from the tail vein of the rat once was quickly injected with an equal amount of buffer.
  • Qualified diabetic rats were randomly divided into 4 groups, and a normal control group was set up.
  • the drug was administered orally once a day for four weeks.
  • the normal and model control groups were intragastrically administered with an equal volume of normal saline, and the positive control group was administered with glibenclamide 1 mg/kg, and the "diabetes preparation group" was administered with "diabetes preparation powder” at a dose equivalent to 17.47 g.
  • the amount of raw drug/kg, containing 1 mg of glibenclamide, the "preparation of the present invention” group is administered with "the preparation powder of the present invention", and the dose is equivalent to 4.32 g of the drug amount/kg, containing 1 mg of glibenclamide.
  • the blood glucose (glucose oxidase method) was taken the next day after stopping the drug to compare the differences between the groups.
  • the preparation method of streptozotocin-induced diabetic rat model is the same as experiment 1.2.2. Forty healthy diabetic rats were randomly divided into 4 groups, and a normal control group was set up. The normal and model control groups were intragastrically administered with an equal volume of normal saline, and the positive control group was administered with glibenclamide 1 mg/kg, and the "diabetes preparation group" was administered with "diabetes preparation powder" at a dose equivalent to 17.47 g.
  • the drug amount/kg contains 1 mg of glibenclamide, and the "preparation of the present invention” group is administered with "the preparation powder of the present invention", and the dose is equivalent to 4.32 g of the drug amount/kg, and contains 1 mg of glibenclamide.
  • the high-fat emulsion (5 ml/kg/time) was administered in the afternoon for 3 weeks.
  • the ether was lightly anesthetized, and the heart was taken for blood cholesterol measurement (ethanol extraction to improve iron-sulfuric acid colorimetry) and triglyceride (enzymatic method - GPO).
  • the glibenclamide group, the “prescription of the present invention” and the “diabetes preparation” have a significant effect on the blood glucose of normal mice and streptozotocin diabetic rats, and the control group. Comparing ⁇ 0.05 or P ⁇ 0.01, there was no significant difference in the hypoglycemic effect between the three; "The preparation of the present invention” has a significant inhibitory effect on the serum total cholesterol and serum triglyceride in diabetic hyperlipidemia rats, and There were significant differences between the control group, the glibenclamide group and the Xiaoke preparation.
  • the present invention rationally optimizes the proportion and combination of prescriptions, and the effect thereof is obviously superior to the "diabetes preparation” and glibenclamide, and the dosage is significantly lower than "
  • the thirst-quenching preparation is convenient for taking and carrying, and provides a safe and effective preparation for the treatment of diabetic patients, and achieves the object of the present invention.
  • the technical solutions of the present invention are further illustrated by some embodiments below.
  • the scutellaria, schisandra and yam are pulverized into a coarse powder. Mix well with the concentrate, dry, pulverize into fine powder, and mix. .
  • the water is pill, dried, added with glibenclamide, coated with black iron oxide, talc and an appropriate amount of binder, light-coated, and dried to form a pellet.
  • the scutellaria, schisandra and yam are pulverized into a coarse powder. Mix well with the concentrate, dry, pulverize into fine powder, and mix. .
  • the water is pill, dried, added with glibenclamide, coated with black iron oxide, talc and an appropriate amount of binder, light-coated, and dried to form a pellet.
  • Astragalus, Schisandra, Yam is pulverized into a coarse powder, mixed with the concentrate, dried, pulverized into fine powder, and added to the grid.
  • Example 4 Preparation of capsules Weigh the raw material Chinese herbal medicine and 1200 parts by weight of glibenclamide - Rehmannia glutinosa, 400 parts by weight of astragalus, 200 parts by weight of yam, 2000 parts by weight of puerarin, 2000 parts by weight of geranium powder, 2000 parts by weight of corn, and 400 parts by weight of schisandra chinensis. 2 ⁇ Glyburide 0. 2 parts by weight. Take Radix Rehmanniae, Radix Puerariae, Trichosanthin, and Corn. Add boiling water for five hours. Filter it. The filtrate is concentrated to an appropriate amount.
  • Astragalus, Schisandra, Yam is pulverized into a coarse powder, mixed with the concentrate, dried, pulverized into fine powder, and added to the grid.
  • Astragalus, Schisandra, Yam is pulverized into a coarse powder, mixed with the concentrate, dried, pulverized into fine powder, and added to the grid.
  • Astragalus, Schisandra, Yam is pulverized into a coarse powder, mixed with the concentrate, dried, pulverized into fine powder, added.
  • the glibenclamide is mixed, and an equal amount of polyethylene glycol-400 and a small amount of glycerin are added and mixed to prepare a soft capsule.
  • rehmannia 500 parts by weight of rehmannia, 200 parts by weight of astragalus, 130 parts by weight of yam, 1100 parts by weight of puerarin, 1200 parts by weight of trichosanthin, 1300 parts by weight of corn, 250 parts by weight of schisandra, and 0.5 parts by weight of glibenclamide.
  • the scutellaria, schisandra and yam are pulverized into a coarse powder. Mix well with the concentrate, dry, pulverize into fine powder, and mix. .
  • the water is pill, dried, black iron oxide, talc and an appropriate amount of binder, and added to the glibenclamide, light-coated, dried, and made into a pellet.
  • Example 12 Preparation of pellets Weigh the raw Chinese herbal medicines and glibenclamide according to the following dosages:
  • the scutellaria, schisandra and yam are pulverized into a coarse powder. Mix well with the concentrate, dry, pulverize into fine powder, and mix. .
  • the water is pill, dried, black iron oxide, talc and an appropriate amount of binder, and added to the glibenclamide, light-coated, dried, and made into a pellet.
  • Astragalus, Schisandra, Yam is pulverized into a coarse powder, mixed with the concentrate, dried, pulverized into fine powder, and added to the grid.
  • Astragalus, Schisandra, Yam is pulverized into a coarse powder, mixed with the concentrate, dried, pulverized into fine powder, and added to the grid.
  • the madol is mixed, and an equal amount of polyethylene glycol-400 and a small amount of glycerin are added and mixed to prepare a soft capsule.
  • Example 16 Preparation of a powder Weigh the raw Chinese herbal medicines and glibenclamide according to the following dosages:

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention décrit une préparation pharmaceutique destinée au traitement du diabète ainsi qu'un procédé de mise en œuvre dudit traitement. Les principes actifs de la préparation pharmaceutique sont élaborés à partir de radix rehmanniae, radix astragali, rhizoma dioscoreae, radix puerariae, radix trichosanthis, stigma maydis, fructus schisandrae sphenantherae, et de glibenclamide. La préparation pharmaceutique a pour effet de renforcer les reins et le yin, d’augmenter l'énergie vitale et de stimuler la production de fluides corporels. La présente invention est employée dans le traitement du diabète dû à une déficience en énergie vitale et en yin, spécifiquement du diabète de type II.
PCT/CN2006/000952 2005-05-18 2006-05-12 Préparation pharmaceutique pour le traitement du diabète et procédé de mise en œuvre dudit traitement WO2006122485A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200510034644.3 2005-05-18
CN200510034644 2005-05-18
CNB2006100750696A CN100355442C (zh) 2005-05-18 2006-03-31 一种治疗糖尿病的药物组合物及其制备方法
CN200610075069.6 2006-03-31

Publications (1)

Publication Number Publication Date
WO2006122485A1 true WO2006122485A1 (fr) 2006-11-23

Family

ID=37388762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/000952 WO2006122485A1 (fr) 2005-05-18 2006-05-12 Préparation pharmaceutique pour le traitement du diabète et procédé de mise en œuvre dudit traitement

Country Status (3)

Country Link
CN (1) CN100355442C (fr)
RU (1) RU2362578C1 (fr)
WO (1) WO2006122485A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012615A2 (fr) 2009-07-30 2011-02-03 Laboratoires Expanscience Composition cosmetique pour le traitement de l'acne comprenant un extrait peptidique de schizandra
WO2011012612A2 (fr) 2009-07-30 2011-02-03 Laboratoires Expanscience Extrait du fruit de schizandra sphenanthera et compositions cosmetiques, dermatologiques et nutraceutiques le comprenant
CN103355674A (zh) * 2013-07-23 2013-10-23 绍兴文理学院 一种猪肚药膳及其制作工艺
CN104544054A (zh) * 2014-12-19 2015-04-29 李进 一种降糖冲剂及其制备方法
CN106334062A (zh) * 2016-09-21 2017-01-18 四川易创生物科技有限公司 一种治疗气血两亏的中药组合物及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101934036B (zh) * 2010-08-26 2013-04-24 广州白云山中一药业有限公司 一种糖尿病治疗药物的制备方法
CN102813840B (zh) * 2011-06-07 2014-08-06 广州白云山中一药业有限公司 一种药物组合物在制备预防和治疗糖尿病心肌病的药物中的应用
CN102836349B (zh) * 2011-06-21 2014-10-15 广州白云山中一药业有限公司 一种治疗糖尿病的中药组合物及其制备方法
CN104991032B (zh) * 2015-07-23 2016-06-08 北京市药品检验所 鉴别五味子中掺杂南五味子的薄层色谱方法
CN105233032A (zh) * 2015-10-20 2016-01-13 李竹岩 治疗糖尿病的中药
CN108079205B (zh) * 2016-11-21 2021-01-19 广州白云山中一药业有限公司 一种中药基质添加格列本脲包衣的方法
CN111567717A (zh) * 2020-05-27 2020-08-25 河南大学 一种山药黏液—纳米氧化锌溶液及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1562188A (zh) * 2004-03-17 2005-01-12 北京奇源益德药物研究所 消渴制剂及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1562188A (zh) * 2004-03-17 2005-01-12 北京奇源益德药物研究所 消渴制剂及其制备方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012615A2 (fr) 2009-07-30 2011-02-03 Laboratoires Expanscience Composition cosmetique pour le traitement de l'acne comprenant un extrait peptidique de schizandra
WO2011012612A2 (fr) 2009-07-30 2011-02-03 Laboratoires Expanscience Extrait du fruit de schizandra sphenanthera et compositions cosmetiques, dermatologiques et nutraceutiques le comprenant
KR20120052991A (ko) * 2009-07-30 2012-05-24 라보라토이레즈 익스펜사이언스 오미자 펩티드 추출물을 포함한 여드름 치료용 화장 조성물
US8586107B2 (en) 2009-07-30 2013-11-19 Laboratoires Expanscience Schisandra sphenanthera fruit extract and cosmetic, dermatological, and nutraceutical compositions comprising same
US8758833B2 (en) 2009-07-30 2014-06-24 Laboratoires Expanscience Cosmetic composition for the treatment of acne comprising a peptide extract of Schisandra
KR101713357B1 (ko) 2009-07-30 2017-03-22 라보라토이레즈 익스펜사이언스 오미자 펩티드 추출물을 포함한 여드름 치료용 화장 조성물
CN103355674A (zh) * 2013-07-23 2013-10-23 绍兴文理学院 一种猪肚药膳及其制作工艺
CN104544054A (zh) * 2014-12-19 2015-04-29 李进 一种降糖冲剂及其制备方法
CN106334062A (zh) * 2016-09-21 2017-01-18 四川易创生物科技有限公司 一种治疗气血两亏的中药组合物及其制备方法

Also Published As

Publication number Publication date
RU2362578C1 (ru) 2009-07-27
CN100355442C (zh) 2007-12-19
CN1861176A (zh) 2006-11-15

Similar Documents

Publication Publication Date Title
WO2006122485A1 (fr) Préparation pharmaceutique pour le traitement du diabète et procédé de mise en œuvre dudit traitement
CN102225149B (zh) 一种治疗糖尿病的中药组合物及其制备方法
CN101352512B (zh) 一种治疗糖尿病的中药组合物及其制备方法
CN105288215A (zh) 一种高活性铁皮石斛冻干粉口含片及其制备工艺
CN102961596B (zh) 一种用于治疗糖尿病的中药组合物及其制备方法和应用
CN103599215A (zh) 一种降糖药物
CN101637561A (zh) 川贝枇杷药物组合物及其制备方法
CN102145120B (zh) 一种适于制备治疗ii型糖尿病的中药组合物
CN102362966A (zh) 川贝枇杷药物组合物及其制备方法
WO2006122454A1 (fr) Composition pharmaceutique pour le traitement du diabete et son procede de preparation
CN103599343A (zh) 一种治疗糖尿病的药物组合物及其制备方法和用途
CN101147767B (zh) 一种治疗痤疮的药物组合物胶囊剂的制备方法
CN107854671A (zh) 阿那日系列蒙药胃内漂浮缓释制剂及其制备方法
CN101455778B (zh) 一种清热利咽的中药制剂及其制备方法
CN112755160A (zh) 一种改善乳腺癌术后预后的中药组合物及其应用
CN107997170B (zh) 一种具有降血脂功能的组合物及其制备方法
CN102178891B (zh) 用于治疗胃炎的中药分散片及其制备方法
CN101884769B (zh) 一种治疗自身免疫性甲状腺炎的中药及生产方法
CN103494894A (zh) 一种具有降低血糖功效的中药组合物及其制备方法和应用
CN103494916A (zh) 一种具有降低血糖功效的中药组合物及其制备方法和应用
CN102058830B (zh) 一种药物组合物制剂及其制备方法
CN107669860A (zh) 一种具有降糖作用的中药组合物及其应用
CN102579801B (zh) 一种治疗糖尿病综合症的中药制剂及其制备方法
CN1136954A (zh) 治糖尿病用中成药及其丸药的生产方法
CN1223360C (zh) 治疗胸痹病症的中药

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2007146284

Country of ref document: RU

Ref document number: 1200702711

Country of ref document: VN

122 Ep: pct application non-entry in european phase

Ref document number: 06741842

Country of ref document: EP

Kind code of ref document: A1